Other Income & Expense
Other Income (Expense)
Vertex Pharmaceuticals Other Income (Expense) decreased by 174.2% to -$9.80M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 42.0%, from -$16.90M to -$9.80M. Over 3 years (FY 2021 to FY 2024), Other Income (Expense) shows a downward trend with a 160.0% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryOther
SignalContext dependent
VolatilityVolatile
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Significant fluctuations often relate to changes in interest rates, investment valuations, or currency volatility.
Detailed definition
The net total of income and expenses from non-operating activities, such as interest income, interest expense, and gains...
Peer comparison
Companies with large cash piles often show significant interest income here, while highly levered firms show interest expense.
Metric ID:
is_other_income_expense_netHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.05M | $42.37M | $7.13M | -$72.80M | -$78.10M | $17.20M | -$31.10M | $1.30M | $1.60M | -$15.90M | -$9.80M | -$31.20M | -$23.10M | -$16.90M | -$14.90M | -$17.60M | $13.20M | -$9.80M |
| QoQ Change | — | +426.2% | -83.2% | <-999% | -7.3% | +122.0% | -280.8% | +104.2% | +23.1% | <-999% | +38.4% | -218.4% | +26.0% | +26.8% | +11.8% | -18.1% | +175.0% | -174.2% |
| YoY Change | — | — | — | — | <-999% | -59.4% | -535.9% | +101.8% | +102.0% | -192.4% | +68.5% | <-999% | <-999% | -6.3% | -52.0% | +43.6% | +157.1% | +42.0% |
Range-$78.10M – $42.37M
CAGR+4.7%
Avg YoY Growth-388.9%
Median YoY Growth-29.2%
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's other income (expense)?
- Vertex Pharmaceuticals (VRTX) reported other income (expense) of -$9.80M in Q3 2025.
- How has Vertex Pharmaceuticals's other income (expense) changed year-over-year?
- Vertex Pharmaceuticals's other income (expense) increased by 42.0% year-over-year, from -$16.90M to -$9.80M.
- What is the long-term trend for Vertex Pharmaceuticals's other income (expense)?
- Over 3 years (2021 to 2024), Vertex Pharmaceuticals's other income (expense) has grown at a 160.0% compound annual growth rate (CAGR), from $4.90M to -$86.10M.
- What does other income (expense) mean?
- Money made or lost from activities not related to the company's main business, like investments or interest.